Growth Metrics

Nexalin Technology (NXL) EBITDA (2021 - 2025)

Nexalin Technology (NXL) has 5 years of EBITDA data on record, last reported at -$2.3 million in Q3 2025.

  • For Q3 2025, EBITDA rose 6.98% year-over-year to -$2.3 million; the TTM value through Sep 2025 reached -$8.7 million, down 55.21%, while the annual FY2024 figure was -$7.6 million, 62.36% down from the prior year.
  • EBITDA reached -$2.3 million in Q3 2025 per NXL's latest filing, down from -$1.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$135401.0 in Q3 2022 and bottomed at -$2.8 million in Q4 2024.
  • Average EBITDA over 5 years is -$1.3 million, with a median of -$1.0 million recorded in 2024.
  • Peak YoY movement for EBITDA: skyrocketed 92.46% in 2022, then tumbled 1620.43% in 2023.
  • A 5-year view of EBITDA shows it stood at -$577489.0 in 2021, then dropped by 16.1% to -$670448.0 in 2022, then decreased by 22.04% to -$818187.0 in 2023, then tumbled by 246.31% to -$2.8 million in 2024, then grew by 19.61% to -$2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$2.3 million in Q3 2025, -$1.6 million in Q2 2025, and -$2.0 million in Q1 2025.